Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Assertio Therapeutics Inc (DE:DPOA)
FRANKFURT:DPOA
Assertio Therapeutics (DPOA) Stock Price & Analysis
1 Followers
DPOA Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.73 - €0.73
Previous Close€0.73
Volume0.00
Average Volume (3M)N/A
Market Cap
€89.35M
Enterprise Value€57.07M
Total Cash (Recent Filing)$73.44M
Total Debt (Recent Filing)$38.51M
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
Aug 01, 2024EPS Estimate
-€0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding105,354,967
10 Day Avg. Volume100
30 Day Avg. VolumeN/A
Standard Deviation0.19
R-Squared0.19
Alpha0.00702
Financial Highlights & Ratios
Price to Book (P/B)1.07
Price to Sales (P/S)0.39
Price to Cash Flow (P/CF)1.50
P/FCF Ratio0.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.38
Enterprise Value/Gross Profit0.46
Enterprise Value/Ebitda-0.27
Forecast
1Y Price Target
€2.76Price Target Upside277.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Assertio Therapeutics News
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
13.61% Other Institutional Investors
86.39% Public Companies and
Individual Investors
DPOA FAQ
What was Assertio Therapeutics Inc’s price range in the past 12 months?
Assertio Therapeutics Inc lowest stock price was €0.73 and its highest was €0.73 in the past 12 months.
What is Assertio Therapeutics Inc’s market cap?
Currently, no data Available
When is Assertio Therapeutics Inc’s upcoming earnings report date?
Assertio Therapeutics Inc’s upcoming earnings report date is Aug 01, 2024 which is in 76 days.
How were Assertio Therapeutics Inc’s earnings last quarter?
Assertio Therapeutics Inc released its earnings results on May 06, 2024. The company reported €0.037 earnings per share for the quarter, beating the consensus estimate of -€0.028 by €0.065.
Is Assertio Therapeutics Inc overvalued?
According to Wall Street analysts Assertio Therapeutics Inc’s price is currently Undervalued.
Does Assertio Therapeutics Inc pay dividends?
Assertio Therapeutics Inc does not currently pay dividends.
What is Assertio Therapeutics Inc’s EPS estimate?
Assertio Therapeutics Inc’s EPS estimate is -€0.03.
How many shares outstanding does Assertio Therapeutics Inc have?
Currently, no data Available
What happened to Assertio Therapeutics Inc’s price movement after its last earnings report?
Assertio Therapeutics Inc reported an EPS of €0.037 in its last earnings report, beating expectations of -€0.028. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Assertio Therapeutics Inc?
Among the largest hedge funds holding Assertio Therapeutics Inc’s share is Gotham Asset Management LLC. It holds Assertio Therapeutics Inc’s shares valued at 28K.
---
Assertio Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€2.76 (277.49% Upside)
€2.76 (277.49% Upside)
Blogger Sentiment
Bullish
DE:DPOA Sentiment 85%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $11.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.02%
12-Months-Change
Fundamentals
Return on Equity
-172.90%
Trailing 12-Months
Asset Growth
-31.94%
Trailing 12-Months
Company Description
Assertio Therapeutics Inc
Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL.
---
DPOA Earnings Call
Q1 2024
0:00 / 0:00
---
DPOA Stock 12 Month Forecast
Average Price Target
€2.76
▲(277.49% Upside)
Technical Analysis
Assertio Therapeutics
―
ACADIA Pharmaceuticals
―
Amarin
―
Assembly Biosciences
―
Axsome Therapeutics
―
Best Analysts Covering DPOA
1 Year
1 Year Success Rate
7/30 ratings generated profit
1 Year Average Return
-27.77%
reiterated a buy rating 6 months ago
Copying Scott Henry's trades and holding each position for 1 Year would result in 23.33% of your transactions generating a profit, with an average return of -27.77% per trade.
---